Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / January / Parkinson's Aggravated by Nanoplastics Exposure
Omics Clinical Omics Metabolomics & Lipidomics

Parkinson's Aggravated by Nanoplastics Exposure

Mouse study suggests environmental nanoplastics may exacerbate Parkinson's disease through metabolic dysregulation in the gut, brain, and liver

By Kathryn Wighton 01/27/2026 3 min read

Share

Polystyrene nanoplastics were evaluated in an A53T α-synuclein mouse model to assess gastrointestinal, metabolic, hepatic, and neurologic outcomes after chronic exposure. In this study, published in npj Parkinson’s Disease, mice were fed polystyrene nanoplastics every other day for three months. This followed intestinal administration of A53T α-synuclein to mimic Parkinson's disease pathology.

The researchers found that mice exposed to nanoplastics had fewer mucus-producing cells in part of the small intestine and more cell death in the gut lining. This happened whether or not the mice carried the A53T α-synuclein gene mutation. The gut bacteria of nano-plastic exposed mice also differed, showing a wider mix of microbes than the control mice, including more of a type of bacteria called Desulfovibrio. Earlier studies have linked this bacterium to the production of hydrogen sulfide—a gas that can damage cells — and to the clumping of the protein α-synuclein. Additional analyses showed that biological pathways related to cell death and the production of inflammatory molecules were more active in the nanoplastic-exposed mice.

Metabolomic profiling of fecal samples identified more than 5,000 metabolites, of which more than 200 showed significant changes in nanoplastic-exposed mice. Many of these altered metabolites were involved in the processing of amino acids, fats, foreign chemicals, and certain drugs. The study also reported significant changes in specific metabolites – including phenylacetylglycine, glycodeoxycholic acid, 7-ketodeoxycholic acid, and 5-hydroxyindole. Histopathologic evaluation of liver tissue demonstrated signs of inflammation in nanoplastic-exposed mice, while levels of cell death in the liver did not differ greatly.

Mass spectrometry of brain tissue detected higher concentrations of A53T α-synuclein when nanoplastics were co-administered. Brain tissue from exposed mice also showed elevated interleukin-6 and lipopolysaccharide levels, and intestinal microbes showed elevated generation of lipopolysaccharide.

Researchers noted that future investigations should include polyethylene, polyamide, charge-neutral particles, and larger microplastic controls to distinguish general nanoplastic effects from those observed with polystyrene. They also indicated that larger, sex-balanced cohorts will be needed to evaluate potential sex-specific responses, as the current sample size limits conclusions in this area.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Kathryn Wighton

Editor, Conexiant

More Articles by Kathryn Wighton

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.